Compare Freeport-McMoRan Inc (FCX) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FCX trades at $72.42, down 1.19% today, with a bullish technical signal from moving averages and a consensus analyst price target of $73.50. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue reached $25.92B in 2025, and net income margin improved to 11.38%. Strong cash flow from operations of $5.61B supports dividend payments and growth projects amid rising copper demand driven by AI and data centers.

FCX presents a positive outlook with robust fundamentals and favorable copper market dynamics, but faces risks from cost pressures and regulatory scrutiny. Earnings growth and expansion initiatives are key catalysts, while investor sentiment remains bullish based on analyst ratings.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.